Harnessing the Power of Stem Cells with Christopher Kennedy, President at Elixell Therapeutics

Outcomes Rocket
|

Automatic TRANSCRIPT

I WANNA welcome Christopher and Chris if you can Say Hi and fill in any other blanks of the intro. That may be. I may have missed that. You want to educate the listeners. Great thank you for hosting this morning and I and I look forward to a really good discussion. Yes so exciting. Time for us here in Kansas City as you mentioned Our offices actually at the Bio Science and Technology Center that's Housed on Kansas University Medical Center campus here in Kansas City. Kansas so this area is essentially set up perfectly for collaborative organization like ourselves. We're really trying to pull in best in class. Researchers best in class practices when it comes to the laboratories themselves the clinical work excited or and so we feel like. We're kind of in a hub here in Kansas City. Even though sometimes we don't think of the midwest of being a hub of innovation. Things are changing here in Kansas City. So I'm excited to represent the the eulex style therapeutic specifically but in the greater community as well. Well I think it's awesome and Christopher the work that is happening outside of those traditionally thought of focal centers like Francisco or Boston or where a lot of the effort seem to be happening. There's more happening in in the flyover states and being in Chicago. Lot happening here. That maybe doesn't always hit the radar so. I'm glad you're plugging in the word for your neck of the Woods Casey. So what exactly inspires your work in healthcare. Yeah so just before we move onto that question saw just kind of highlight what you just mentioned there Interestingly enough we have thirteen patents and our Ip actually comes from the Towers Institute which is based here in Kansas City. And before I moved to the area I also was not as aware of the great technologies that have come out of this particular geography but the Stars Institute for for listeners. That aren't familiar with. It is a global research institute. It's a six hundred thousand square foot facility here in Kansas City. And this is one of the first license out license technologies. That has come out of there. That eulex therapeutics has the privilege of working on. But Yeah it's to your point as well. I mean I grew up in the Chicago area. Also another great hub of innovation and ironically on this project that I'm working with there's actually a Chicago footprint as well as a Kansas City footprint. So yeah more than ever my wave in the Midwest flag so love it represents you get to your question about what inspires healthcare. I I find it interesting when I think of your title so outcomes rocket my career has been really focused on patient outcomes and I I love the term. I know that it's probably becoming more and more use potentially over using some regards now on the healthcare circle but I love it because it really aligns with a scoreboard right like a performance scoreboard where we at and where we going and he looks. Therapeutics was constructed on the premise of we can go further when it comes to stem cells particularly the advanced themselves sciences and when. I say themselves from our perspective. I'm talking about poetics. Themselves with adult stem cells versus the embryonic stem cells. That are in the media today so H. SC's are the focus for us because there is so much potential around the therapeutic side of what can be in the future in a lot of our umbilical cord banks throughout not just the US but worldwide and so- outcomes are clearly are focused. Here's walls. We feel that we can utilize a new technologies to really impact the patient at the bedside here in the near future. Yeah that's interesting and appreciate the differentiation there. Christopher what would you say? The business is doing specifically to add value to the healthcare ecosystem. Help US diving deeper and understand what the value prop is. Yeah and I think. This is a benefit to watching a company in twenty twenty to be frank right that we've been able to capitalize maximize the opportunities that exist. Now you mentioned earlier on the intro. Some of the work that I had done the telemedicine virtual care space and never. Is that more important in. Today's I think clinical time but also when it comes to clinical research so we're global organization and we have ties to Asia Europe. And then of course here in the US but our researchers are really in a full term of collaborative research together. And so we've cut down. I think a lot of the time. Line that traditionally this taken to get all the parties set up and ready to go when I come. You know for clinical work for example or just on a project in general and working with academic institutions large research institutions like the University of Chicago or Kansas University of Kansas and being able to transition Ip out and then get the research up and running is really been something that we focused on early on and successfully. I feel that we are implementing that and the proof point of that right. The outcome of what I just mentioned would be our scientific advisory board so traditionally in my experience. The Scientific Advisory Board for Big Pharma Small Pharma Biotech Med device and all of those spaces is very critical in the direction organization. Takes but just on our scientific advisory board. We've got six globally world-renowned research academic type Individuals who I think in years past without the you know. The advent of some of our current technologies would have taken a lot longer to get together and working on the same project so institutions like Penn. Yeah we have University of Chicago Ball University of Indiana researchers from University of Kansas. That I mentioned earlier Stars Institute all sitting on our advisory board and it allows for us to cut down the time it takes potentially to have a novel concept or an idea in them tested on the laboratory taxi tested in our early clinical phase. To See if it's viable or not and then to get feedback from a global perspective from the SAB. The Scientific Advisory Board has been instrumental. So the right now. We know the to pass. The Ron have the best chance to reach their outcome at the end for patients. Love it so if you think about what makes what you and the company does different and better than what available today. What is it so let's talk about the technology rising when to that ASPECT OF HSE STEM CELL? Topic is big. And there's essentially what I feel some sort of a race going on for getting technology into the marketplace that allows us to really recognize all of the stem cell opportunities within Belco cords themselves. Right so just says as a layman that I was entering into this project really understanding of the D. N. A. M. R. N. A. Aspect of of how life is working and uncovering the researchers that we have the privilege to interact with on our team published a really important and I would definitely classify this as a breakthrough paper and this was specific to and cell research the suppression of success a reader. Which is the White Dwarf to that? We're focused on under these. This category of an fix a reader and six say reader modulators essentially an expression of of Mres right so when we talk about DNA and the communication channels within cells. There's a communication that happens that really specific to stem cell fate determination. And what we've done is uncovered that with whites. Hdf to Professor Lynne. Hanley in Schwann. He both uncovered the fact that when you knock out whites. Hdf to all of the sudden we start to see a really successful stem cell expansion so one becomes two to become a three and so on and so forth and this stem cell expansion allows us to take potential biblical cord banks that are out there today and really go head into the challenge of having limited cells that are available and these banks. So you have all these blood cord banks that are out there. But the issue is both uncovering the actual cells themselves. So how many cells are stored right within the blood cord and then getting them so that we can have more of them essentially and what we're learning now on what's going on in our lab is how do we use this white T H D of. Two knockout or blocking mechanism to then help those cells. We already have in a bank expand and they'd be more therapeutically viable for diseases. Let's talk about oncology. For example where one of our first pipeline products is currently underway. Also from an orthopedic application when you think about cartilage regeneration so stem cells and set them themselves allow us to have the potential to really impact in a really large number of different disease states. And I think we're on the cutting edge of being able to recognize how powerful discoveries like this can be and that's our big differentiation. Salt as you know and my stays being a part of an early stage biotech. We pivot often. So we're we're starting right now. We've already moved a few places to the left or to the right to get to our early clinical work but that's our differentiation. Today is definitely the publication that kind of expresses what we're doing under why Tgif to interesting and so appreciate you you're honing in on that Whitey HD F two and it's basically this isn't my specialty but it's a protein right that basically encodes a gene and potentially is responsible for some of the diseases. Were seeing cancer will. What we know is. The setback forced themselves their piece today. Is it's hard to get the volume of a number of cells and into the correct location. Potentially do their job. And because of that that limitation. It's almost a self limitation of pure numbers. Race is on to find out well. How do we unlock the potential for those souls that we currently have banked become more and so when you block white t? Hdf to their allows in a particularly in the actual article that was published by Lynne. Hanley and Sean. He led the more than tenfold increase and the bench. So big you're looking and then when you look at measuring evidence no you can't no it is a From a scientific terminology standpoint. It's an say reader. But there's a modulation aspect of that right because these in Marin as when you essentially modify or work with the actual Ima- reader than the the results can happen like we're seeing in this clinical work. Now we still have more more work to do on this front right. And so that's where research is currently going on and the human element of things but in the animal models It's really impressive. And so where we sit today were versus where we'll sit even twelve. Eighteen months from now is exciting and every day. We're looking at Trends right and so I feel like you know again back to our term outcomes. That's the common language between layman like ourselves. That aren't biochemist right or molecular biologist and for us to hang in conversations with our backgrounds on more the business side of healthcare we all can agree upon is. What are the outcomes that we're looking for in the clinical work in what our objectives are overall? And so we've done that. I think successfully Here in the early stages to kind of keep us on track and also we've been very very fortunate to sit on University of Kansas medical centers. Campus where we are working with. It's called Ami if you're here locally but it's Institute for Advancing Medical Innovation at Ku and this group is essentially a gold standard for what we've been talking about in this call so so far and that is taking best in class practices and taking a true collaborative approach to getting something that was discovered in a laboratory getting through clinical trial work. And then. Really getting out to patient bedside. Where it's driving these outcomes so I think that's been refreshing for me to see not just like the theory of how do you launch a biotech company but then to actually being a place where these resources already set up and it's really helping our

Coming up next